ES2633762T3 - Hipertensión e hiperuricemia - Google Patents

Hipertensión e hiperuricemia Download PDF

Info

Publication number
ES2633762T3
ES2633762T3 ES12789268.5T ES12789268T ES2633762T3 ES 2633762 T3 ES2633762 T3 ES 2633762T3 ES 12789268 T ES12789268 T ES 12789268T ES 2633762 T3 ES2633762 T3 ES 2633762T3
Authority
ES
Spain
Prior art keywords
hyperuricemia
hypertension
lesinurad
allopurinol
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12789268.5T
Other languages
English (en)
Inventor
Jeffrey Miner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ardea Biociences Inc
Original Assignee
Ardea Biociences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47217678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2633762(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biociences Inc filed Critical Ardea Biociences Inc
Application granted granted Critical
Publication of ES2633762T3 publication Critical patent/ES2633762T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
    • C07D285/28—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Lesinurad o una sal farmacéuticamente aceptable de este y alopurinol para usar en el tratamiento de la gota en un paciente que, además, se trata con un diurético tiazídico.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
ES12789268.5T 2011-05-24 2012-05-22 Hipertensión e hiperuricemia Active ES2633762T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161489597P 2011-05-24 2011-05-24
US201161489597P 2011-05-24
PCT/US2012/039011 WO2012162323A1 (en) 2011-05-24 2012-05-22 Hypertension and hyperuricemia

Publications (1)

Publication Number Publication Date
ES2633762T3 true ES2633762T3 (es) 2017-09-25

Family

ID=47217678

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12789268.5T Active ES2633762T3 (es) 2011-05-24 2012-05-22 Hipertensión e hiperuricemia

Country Status (27)

Country Link
US (1) US20140171424A1 (es)
EP (1) EP2714669B1 (es)
JP (1) JP5964952B2 (es)
KR (1) KR101624023B1 (es)
CN (1) CN103702986A (es)
AU (1) AU2012258860B2 (es)
BR (1) BR112013030078A2 (es)
CA (1) CA2837080C (es)
CY (1) CY1119156T1 (es)
DK (1) DK2714669T3 (es)
EA (1) EA201370247A1 (es)
ES (1) ES2633762T3 (es)
HR (1) HRP20171054T1 (es)
HU (1) HUE033868T2 (es)
IL (1) IL229537A0 (es)
LT (1) LT2714669T (es)
MX (1) MX348281B (es)
MY (1) MY163930A (es)
NZ (1) NZ618373A (es)
PL (1) PL2714669T3 (es)
PT (1) PT2714669T (es)
RS (1) RS56225B1 (es)
SG (1) SG195112A1 (es)
SI (1) SI2714669T1 (es)
UA (1) UA109943C2 (es)
WO (1) WO2012162323A1 (es)
ZA (1) ZA201308807B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ595035A (en) 2007-11-27 2012-11-30 Ardea Biosciences Inc Substituted diazole and triazole compounds and compositions and methods of use
EP3659601A1 (en) 2010-03-30 2020-06-03 Ardea Biosciences, Inc. Treatment of gout
SI2582683T1 (en) 2010-06-15 2018-07-31 Ardea Biosciences, Inc. Treatment of gout and hyperuricaemia
CN104311452B (zh) * 2014-09-27 2016-01-06 张远强 腈基萘环的丁二酸酰胺衍生物、其制备方法及用途
CN104292124B (zh) * 2014-09-27 2016-01-20 张远强 硝基苯基取代的萘环丁二酸酰胺衍生物、其制备方法及用途
KR102487604B1 (ko) * 2020-11-06 2023-01-12 에스케이케미칼 주식회사 히드로플루메티아지드를 유효성분으로 포함하는 TNF-α 관련 질환 예방 또는 치료용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4675586B2 (ja) * 2004-06-23 2011-04-27 壽製薬株式会社 高血圧症及び血清高尿酸血症の重複発症の治療のための薬剤
US20090054319A1 (en) * 2005-03-17 2009-02-26 Microbia, Inc. Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders
NZ595035A (en) * 2007-11-27 2012-11-30 Ardea Biosciences Inc Substituted diazole and triazole compounds and compositions and methods of use
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
CA2735828C (en) * 2008-09-04 2013-07-23 Esmir Gunic Substituted-(naphthalen-1-yl)-1h-imidazoles and their use for modulating uric acid levels

Also Published As

Publication number Publication date
KR20140023396A (ko) 2014-02-26
EP2714669A4 (en) 2015-01-07
AU2012258860B2 (en) 2015-12-03
BR112013030078A2 (pt) 2016-08-09
CN103702986A (zh) 2014-04-02
DK2714669T3 (en) 2017-08-07
NZ618373A (en) 2015-10-30
SG195112A1 (en) 2013-12-30
CY1119156T1 (el) 2018-02-14
MX2013013655A (es) 2014-08-21
US20140171424A1 (en) 2014-06-19
UA109943C2 (xx) 2015-10-26
KR101624023B1 (ko) 2016-05-24
CA2837080A1 (en) 2012-11-29
HUE033868T2 (en) 2018-01-29
EP2714669A1 (en) 2014-04-09
PT2714669T (pt) 2017-07-21
EP2714669B1 (en) 2017-04-26
IL229537A0 (en) 2014-01-30
RS56225B1 (sr) 2017-11-30
EA201370247A1 (ru) 2014-07-30
JP5964952B2 (ja) 2016-08-03
SI2714669T1 (sl) 2017-10-30
MY163930A (en) 2017-11-15
ZA201308807B (en) 2019-07-31
JP2014515376A (ja) 2014-06-30
HRP20171054T1 (hr) 2017-10-06
LT2714669T (lt) 2017-08-10
PL2714669T3 (pl) 2017-09-29
AU2012258860A1 (en) 2014-01-09
MX348281B (es) 2017-06-02
WO2012162323A1 (en) 2012-11-29
CA2837080C (en) 2017-01-24

Similar Documents

Publication Publication Date Title
ES2633762T3 (es) Hipertensión e hiperuricemia
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
ES2515168T3 (es) Detección y tratamiento de la esquizofrenia
ES2634562T3 (es) Métodos y composiciones para tratar hiperuricemia y trastornos metabólicos asociados con hiperuricemia
ES2493316T3 (es) GLYX-13 para uso en un método para tratar depresión que no responde al tratamiento
CL2014000297A1 (es) Uso de un inhibidores de corrientes "funny" (if) o una de sus sales para utilizar en un metodo de tratamiento y prevencion de la insuficiencia cardiaca en felinos .
ES2665917T3 (es) Endoxifeno para su uso en el tratamiento del cáncer
ES2496092T3 (es) El uso de amisulprida para tratar náuseas y vómitos posoperatorios
CL2016000405A1 (es) Uso de bardoxolón metilo o análogos del mismo para el tratamiento y/o prevención de la disfunción endotelial.
GT201300320A (es) Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer.
ES2552654T3 (es) Uso de LCAT para tratar la anemia y la disfunción de los glóbulos rojos
AR087693A1 (es) Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
CL2017000050A1 (es) Terapia de combinación para el cáncer
ES2689971T3 (es) Uso de inhibidores de PDE7 para el tratamiento de los trastornos del movimiento
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
ES2660019T3 (es) Parche que contiene diclofenaco y tiocolchicósido
CL2017002293A1 (es) Tratamiento de pacientes con diabetes mellitus de tipo 2
CL2019000377A1 (es) Compuesto para uso en el tratamiento de hipotensión ortostática neurogénica.
ES2609817T3 (es) Leucotoxina E/D como nuevo agente antiinflamatorio y microbicida
ES2529434T3 (es) Método para tratar neoplasias hematopoyéticas
ES2640752T3 (es) Agonistas del receptor 5-HT4 para el tratamiento de la demencia
ES2534911T3 (es) Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
AR080933A1 (es) Tratamiento de esclerosis multiple con masitinib
ES2611776T3 (es) Uso de sales de tungsteno (VI) para el tratamiento de la esterilidad femenina en mamíferos no diabéticos